Citigroup
ALXO icon

Citigroup’s ALX Oncology ALXO Stock Holding History

Citigroup’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
50,635
+50,618
+297,753% +$90.6K ﹤0.01% 4661
2026
Q1 		$34 Buy
+17
New +$32 ﹤0.01% 5670
2025
Q4 		– Sell
-2,278
Closed -$4.17K – 6036
2025
Q3 		$4.17K Sell
2,278
-6,732
-75% -$5.83K ﹤0.01% 5280
2025
Q2 		$3.74K Sell
9,010
-15,701
-64% -$7.92K ﹤0.01% 5313
2025
Q1 		$15.4K Sell
24,711
-6,725
-21% -$8.07K ﹤0.01% 5135
2024
Q4 		$52.5K Buy
31,436
+5,884
+23% +$9.04K ﹤0.01% 5071
2024
Q3 		$46.5K Buy
25,552
+17,260
+208% +$64.2K ﹤0.01% 5042
2024
Q2 		$50K Sell
8,292
-35,215
-81% -$433K ﹤0.01% 4577
2024
Q1 		$485K Buy
43,507
+38,764
+817% +$544K ﹤0.01% 3596
2023
Q4 		$70.6K Buy
4,743
+4,220
+807% +$40K ﹤0.01% 4357
2023
Q3 		$2.51K Sell
523
-6,616
-93% -$35.9K ﹤0.01% 4904
2023
Q2 		$53.6K Buy
7,139
+6,214
+672% +$40.7K ﹤0.01% 4604
2023
Q1 		$4.18K Sell
925
-189
-17% -$1.43K ﹤0.01% 4983
2022
Q4 		$12.6K Sell
1,114
-142
-11% -$1.59K ﹤0.01% 4771
2022
Q3 		$12K Sell
1,256
-1,336
-52% -$15.6K ﹤0.01% 4919
2022
Q2 		$21K Sell
2,592
-22,591
-90% -$246K ﹤0.01% 4961
2022
Q1 		$426K Sell
25,183
-61,494
-71% -$1.05M ﹤0.01% 3620
2021
Q4 		$1.86M Buy
86,677
+63,311
+271% +$2.73M ﹤0.01% 2685
2021
Q3 		$1.73M Sell
23,366
-46,103
-66% -$3.07M ﹤0.01% 2656
2021
Q2 		$3.8M Buy
69,469
+14,779
+27% +$884K ﹤0.01% 2153
2021
Q1 		$4.03M Buy
54,690
+51,499
+1,614% +$4.05M ﹤0.01% 1944
2020
Q4 		$275K Sell
3,191
-463
-13% -$27.9K ﹤0.01% 4743
2020
Q3 		$138K Buy
+3,654
New +$144K ﹤0.01% 4877

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Citigroup's ALXO Position: Q2 2026 in Review

Citigroup increased its ALX Oncology (ALXO) stake by 297,753% in Q2 2026, buying an estimated $90.6K and bringing the position to 50,635 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #4661.

Citigroup first reported a position in ALXO in Q3 2020 and has held it in 23 quarters since. The position peaked at $4.03M in Q1 2021. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Citigroup held 50,635 shares of ALX Oncology worth $105K as of Q2 2026.
  • Citigroup bought 50,618 ALX Oncology shares in Q2 2026, an estimated $90.6K.
  • ALX Oncology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4661 holding.
  • Citigroup first reported a position in ALX Oncology in Q3 2020 and has held it in 23 quarters since.
  • Citigroup's ALX Oncology position peaked at $4.03M in Q1 2021.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.